首页 / 院系成果 / 成果详情页

Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study 期刊论文

编号：

F524007F5D9F0B08E5C2A78988FE7FAD
作者：

Yang, JinJi#^[1]Mu, Yu#^[2]Wang, ZheHai^[3];Duan, JianChun^[4];Zhang, Yan^[5];Wu, Lin^[6];Zhong, Hua^[7];Zhao, Jun^[8];Yao, Yu^[9];Wang, Ping^[10];Li, XiaoLing^[11];Yang, RunXiang^[12];Min, XuHong^[13];Lv, DongQing^[14];Xu, HaiPeng^[15];Fu, ZhenMing^[16];Shen, Bo^[17];Sun, LongHua^[18];Wang, ChangLi(王长利)^[19]Zhou, JianYa^[20];Xu, RuiLian^[21];Ma, HuiWen^[22];Zhao, YanQiu^[2];Shi, HePeng^[23];Zhang, PeiLong^[23];Xue, WeiZhe^[24];Han, Di^[25];Zheng, Yi^[25];Wu, YiLong*^[1]
语种：

英文
期刊：

JOURNAL OF THORACIC ONCOLOGY ISSN：1556-0864 2026 年 21 卷 3 期 ; MAR
收录：
关键词：

EGFR exon 20 insertion Non-small cell lung cancer Tyrosine kinase inhibitor Andamertinib Targeted therapy
摘要：

Objectives: This study aimed to evaluate andamertinib, a selective and irreversible tyrosine kinase inhibitor, in pretreated advanced EGFR exon 20 insertion (ex20ins)-mutant NSCLC. Methods: In the phase 2, multicenter, single-arm KANNON study (NCT06015503), patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who had progressed after platinum-based chemotherapy or immunotherapy received oral andamertinib 240 mg once daily in 28-day cycles. The primary end point was the confirmed objective response rate (ORR) assessed by independent review. Results: A total of 92 patients were enrolled and received daily 240 mg andamertinib, with nearly 30 different exo-n20ins subtypes included. The confirmed ORR was 42.7% (95% confidence interval [CI], 32.4-53.0), with a disease control rate of 86.5% and a median duration of response of 8.7 months (95% CI, 5.65-11.96). As of September 6, 2025, with a median follow-up of 15.4 (range, 0.4-20.5) months, the median progression-free survival was 6.2 months (95% CI, 4.63-7.85) and median overall survival was not reached (95% CI, 13.93 mo to not estimable), with a 12-month survival rate of 70.5%. Among 38 patients with brain metastasis, the systemic confirmed ORR was 47.4% (95% CI, 31.5-63.2). Grade more than or equal to 3 treatment-related adverse events occurred in 40.2% of patients, and the most frequent events were diarrhea (12.0%) and rash (7.6%). No interstitial lung disease or grade more than or equal to 3 QT prolongation was reported. Conclusions: Andamertinib at 240 mg once daily demonstrated efficacy with a manageable safety profile in previously treated patients with EGFR ex20ins-mutant NSCLC. (c) 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
推荐引用方式
GB/T 7714：

Yang Jin-Ji,Mu Yu,Wang Zhe-Hai, et al. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study [J].JOURNAL OF THORACIC ONCOLOGY,2026,21(3).
APA：

Yang Jin-Ji,Mu Yu,Wang Zhe-Hai,Duan Jian-Chun,&Wu Yi-Long.(2026).Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study .JOURNAL OF THORACIC ONCOLOGY,21(3).
MLA：

Yang Jin-Ji, et al. "Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study" .JOURNAL OF THORACIC ONCOLOGY 21,3(2026).
入库时间：

3/26/2026 9:26:33 PM
更新时间：

3/26/2026 9:26:33 PM

浏览次数：14  下载次数：0

分享到：

浏览次数：14

下载次数：0

打印次数：0